Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALT Altimmune	$3.83 -1.5%	$3.76	$2.90 ▼ $11.16	$338.02M	0.07	2.93 million shs	2.13 million shs
AMGN Amgen	$298.81 +1.0%	$287.14	$253.30 ▼ $335.88	$160.87B	0.49	2.72 million shs	1.96 million shs
ENDP Endo International		$0.45	$0.28 ▼ $7.07	$141K	1.15	28.19 million shs	9,967 shs
LLY Eli Lilly and Company	$803.53 -1.9%	$753.09	$623.78 ▼ $935.63	$759.84B	0.47	3.82 million shs	3.98 million shs
PFE Pfizer	$24.52 +1.2%	$24.89	$20.92 ▼ $29.36	$139.35B	0.55	63.48 million shs	40.04 million shs
VKTX Viking Therapeutics	$33.53 -3.5%	$29.23	$18.92 ▼ $81.73	$3.77B	0.64	5.23 million shs	4.04 million shs

7 Stocks to Ride The A.I. Megaboom

We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALT Altimmune	0.00%	-2.30%	-1.03%	-6.13%	-44.17%
AMGN Amgen	0.00%	+2.99%	+8.33%	+1.37%	-7.10%
ENDP Endo International	0.00%	0.00%	0.00%	0.00%	0.00%
LLY Eli Lilly and Company	0.00%	-3.55%	+5.33%	+4.11%	-12.31%
PFE Pfizer	0.00%	-1.17%	+1.49%	+0.22%	-17.35%
VKTX Viking Therapeutics	0.00%	-0.09%	+28.76%	+4.75%	-49.08%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALT Altimmune	$3.83 -1.5%	$3.76	$2.90 ▼ $11.16	$338.02M	0.07	2.93 million shs	2.13 million shs
AMGN Amgen	$298.81 +1.0%	$287.14	$253.30 ▼ $335.88	$160.87B	0.49	2.72 million shs	1.96 million shs
ENDP Endo International		$0.45	$0.28 ▼ $7.07	$141K	1.15	28.19 million shs	9,967 shs
LLY Eli Lilly and Company	$803.53 -1.9%	$753.09	$623.78 ▼ $935.63	$759.84B	0.47	3.82 million shs	3.98 million shs
PFE Pfizer	$24.52 +1.2%	$24.89	$20.92 ▼ $29.36	$139.35B	0.55	63.48 million shs	40.04 million shs
VKTX Viking Therapeutics	$33.53 -3.5%	$29.23	$18.92 ▼ $81.73	$3.77B	0.64	5.23 million shs	4.04 million shs

7 Stocks to Ride The A.I. Megaboom

The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALT Altimmune	0.00%	-2.30%	-1.03%	-6.13%	-44.17%
AMGN Amgen	0.00%	+2.99%	+8.33%	+1.37%	-7.10%
ENDP Endo International	0.00%	0.00%	0.00%	0.00%	0.00%
LLY Eli Lilly and Company	0.00%	-3.55%	+5.33%	+4.11%	-12.31%
PFE Pfizer	0.00%	-1.17%	+1.49%	+0.22%	-17.35%
VKTX Viking Therapeutics	0.00%	-0.09%	+28.76%	+4.75%	-49.08%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALT Altimmune	2.38	Hold	$17.40	354.31% Upside
AMGN Amgen	2.32	Hold	$305.50	2.24% Upside
ENDP Endo International	0.00	N/A	N/A	N/A
LLY Eli Lilly and Company	2.67	Moderate Buy	$939.12	16.87% Upside
PFE Pfizer	2.39	Hold	$28.13	14.73% Upside
VKTX Viking Therapeutics	2.86	Moderate Buy	$86.42	157.73% Upside

Current Analyst Ratings Breakdown

Latest VKTX, AMGN, LLY, ENDP, PFE, and ALT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/16/2025	LLY Eli Lilly and Company	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$948.00
10/14/2025	LLY Eli Lilly and Company	Erste Group Bank Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold ➝ Buy
10/10/2025	PFE Pfizer	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Equal Weight	$33.00 ➝ $32.00
10/10/2025	ALT Altimmune	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$12.00
10/10/2025	LLY Eli Lilly and Company	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$876.00 ➝ $879.00
10/9/2025	LLY Eli Lilly and Company	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target	Overweight	$925.00
10/8/2025	LLY Eli Lilly and Company	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$875.00 ➝ $948.00
10/8/2025	ALT Altimmune	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
10/8/2025	AMGN Amgen	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold (C+) ➝ Buy (B-)
10/8/2025	LLY Eli Lilly and Company	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Hold (C+)
10/8/2025	PFE Pfizer	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Hold (C-)

(Data available from 10/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALT Altimmune	$20K	16,901.22	N/A	N/A	$1.74 per share	2.20
AMGN Amgen	$34.92B	4.61	$30.37 per share	9.84	$10.93 per share	27.34
ENDP Endo International	$2.99B	0.00	N/A	0.06	($13.60) per share	0.00
LLY Eli Lilly and Company	$45.04B	16.88	$14.25 per share	56.40	$15.03 per share	53.46
PFE Pfizer	$63.63B	2.19	$4.36 per share	5.62	$15.62 per share	1.57
VKTX Viking Therapeutics	N/A	N/A	N/A	N/A	$7.90 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALT Altimmune	-$95.06M	-$1.18	N/A	N/A	N/A	-438,730.03%	-62.63%	-55.29%	11/11/2025 (Estimated)
AMGN Amgen	$4.09B	$12.23	24.43	13.97	2.64	18.96%	174.71%	13.12%	11/4/2025 (Estimated)
ENDP Endo International	-$613.24M	-$11.07	N/A	0.00	N/A	-93.31%	-34.25%	6.72%	N/A
LLY Eli Lilly and Company	$10.59B	$15.30	52.52	25.82	1.15	25.91%	92.72%	16.89%	10/30/2025 (Estimated)
PFE Pfizer	$8.03B	$1.88	13.04	8.09	0.81	16.84%	21.42%	9.12%	11/4/2025 (Estimated)
VKTX Viking Therapeutics	-$109.96M	-$1.53	N/A	N/A	N/A	N/A	-19.98%	-19.38%	10/22/2025 (Estimated)

Latest VKTX, AMGN, LLY, ENDP, PFE, and ALT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/11/2025	Q3 2025	ALT Altimmune	-$0.29	N/A	N/A	N/A	$0.00 million	N/A
11/4/2025	Q3 2025	AMGN Amgen	$5.01	N/A	N/A	N/A	$8.98 billion	N/A
11/4/2025	Q3 2025	PFE Pfizer	$0.79	N/A	N/A	N/A	$16.94 billion	N/A
10/30/2025	Q3 2025	LLY Eli Lilly and Company	$6.42	N/A	N/A	N/A	$16.09 billion	N/A
10/22/2025	Q3 2025	VKTX Viking Therapeutics	-$0.71	N/A	N/A	N/A	N/A	N/A
8/12/2025	Q2 2025	ALT Altimmune	-$0.32	-$0.27	+$0.05	-$0.27	$0.00 million	$0.01 million
8/7/2025	Q2 2025	LLY Eli Lilly and Company	$5.59	$6.31	+$0.72	$6.29	$14.40 billion	$15.56 billion
8/5/2025	Q2 2025	AMGN Amgen	$5.28	$6.02	+$0.74	$2.65	$8.86 billion	$9.18 billion
8/5/2025	Q2 2025	PFE Pfizer	$0.58	$0.78	+$0.20	$0.51	$13.43 billion	$14.65 billion
7/23/2025	Q2 2025	VKTX Viking Therapeutics	-$0.44	-$0.58	-$0.14	-$0.58	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALT Altimmune	N/A	N/A	N/A	N/A	N/A
AMGN Amgen	$9.52	3.19%	N/A	77.84%	14 Years
ENDP Endo International	N/A	N/A	N/A	N/A	N/A
LLY Eli Lilly and Company	$6.00	0.75%	N/A	39.22%	11 Years
PFE Pfizer	$1.72	7.02%	N/A	91.49%	16 Years
VKTX Viking Therapeutics	N/A	N/A	N/A	N/A	N/A

Latest VKTX, AMGN, LLY, ENDP, PFE, and ALT Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
10/9/2025	PFE Pfizer	quarterly	$0.43	6.82%	11/7/2025	11/7/2025	12/1/2025
8/1/2025	AMGN Amgen	quarterly	$2.38	3.21%	8/22/2025	8/22/2025	9/12/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALT Altimmune	0.09	20.44	20.44
AMGN Amgen	7.24	1.31	0.98
ENDP Endo International	N/A	1.86	1.62
LLY Eli Lilly and Company	1.86	1.28	1.00
PFE Pfizer	0.65	1.16	0.85
VKTX Viking Therapeutics	N/A	25.86	25.86

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALT Altimmune	78.05%
AMGN Amgen	76.50%
ENDP Endo International	80.39%
LLY Eli Lilly and Company	82.53%
PFE Pfizer	68.36%
VKTX Viking Therapeutics	76.03%

Insider Ownership

Company	Insider Ownership
ALT Altimmune	4.40%
AMGN Amgen	0.76%
ENDP Endo International	1.20%
LLY Eli Lilly and Company	0.13%
PFE Pfizer	0.06%
VKTX Viking Therapeutics	4.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALT Altimmune	50	88.26 million	84.37 million	Optionable
AMGN Amgen	28,000	538.36 million	534.27 million	Optionable
ENDP Endo International	3,103	235.14 million	232.32 million	No Data
LLY Eli Lilly and Company	47,000	946.46 million	945.23 million	Optionable
PFE Pfizer	81,000	5.69 billion	5.68 billion	Optionable
VKTX Viking Therapeutics	20	112.45 million	107.84 million	Optionable

VKTX, AMGN, LLY, ENDP, PFE, and ALT Headlines

Recent News About These Companies

Viking Therapeutics (VKTX) Receives a Buy from Oppenheimer

October 17 at 12:12 AM | finance.yahoo.com

Trump jab sinks NVO, LLY, VKTX, AMGN, ALT

October 17 at 7:11 PM | nai500.comN

Viking Therapeutics, Inc. (VKTX) Stock Dips While Market Gains: Key Facts

October 17 at 6:45 PM | zacks.com

Viking Therapeutics (NASDAQ:VKTX) Trading Down 3.4% - Time to Sell?

October 17 at 5:40 PM | marketbeat.com

Viking Therapeutics (NASDAQ:VKTX) Shares Gap Down - Here's What Happened

October 17 at 12:18 PM | marketbeat.com

Pre-Q3 Earnings: Is Viking Therapeutics Stock a Portfolio Must-Have?

October 17 at 10:31 AM | zacks.com

Who Will Dominate the Next Generation of Weight-Loss Drugs? The Fierce Battle Between Eli Lilly and Viking

October 17 at 4:41 AM | nai500.comN

Eli Lilly vs. Viking Therapeutics Stock: Which Is the Best Growth Opportunity, According to Wall Street?

October 17 at 4:41 AM | fool.com

RFG Advisory LLC Acquires 25,387 Shares of Viking Therapeutics, Inc. $VKTX

October 16 at 4:48 AM | marketbeat.com

Viking Therapeutics to Report Financial Results for Third Quarter 2025 on October 22, 2025

October 15, 2025 | prnewswire.com

Viking Therapeutics (VKTX) Projected to Post Earnings on Wednesday

October 15, 2025 | marketbeat.com

Viking Therapeutics, Inc. (VKTX) Registers a Bigger Fall Than the Market: Important Facts to Note

October 14, 2025 | zacks.com

Viking Therapeutics (NASDAQ:VKTX) Shares Down 2.5% - Should You Sell?

October 14, 2025 | marketbeat.com

Viking Therapeutics (NASDAQ:VKTX) Trading Up 1% - What's Next?

October 13, 2025 | marketbeat.com

IFP Advisors Inc Acquires 10,048 Shares of Viking Therapeutics, Inc. $VKTX

October 13, 2025 | marketbeat.com

M&A Speculation Fuels Volatility in Viking Therapeutics Shares

October 12, 2025 | aktiencheck.deA

Viking Therapeutics, Inc. $VKTX Shares Acquired by Blair William & Co. IL

October 12, 2025 | marketbeat.com

Viking Therapeutics (NASDAQ:VKTX) Shares Down 4.1% - What's Next?

October 10, 2025 | marketbeat.com

Wealth Enhancement Advisory Services LLC Purchases New Stake in Viking Therapeutics, Inc. $VKTX

October 10, 2025 | marketbeat.com

Viking Therapeutics (NASDAQ:VKTX) Stock Price Up 8.1% - Should You Buy?

October 10, 2025 | marketbeat.com

Viking Therapeutics, Inc. (NASDAQ:VKTX) Given Average Recommendation of "Moderate Buy" by Brokerages

October 9, 2025 | americanbankingnews.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

VKTX, AMGN, LLY, ENDP, PFE, and ALT Company Descriptions

Altimmune NASDAQ:ALT

$3.83 -0.06 (-1.54%)

Closing price 10/17/2025 04:00 PM Eastern

Extended Trading

$3.86 +0.02 (+0.65%)

As of 10/17/2025 07:56 PM Eastern

Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.

Amgen NASDAQ:AMGN

$298.81 +3.00 (+1.01%)

Closing price 10/17/2025 04:00 PM Eastern

Extended Trading

$300.40 +1.59 (+0.53%)

As of 10/17/2025 07:58 PM Eastern

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.

Endo International NASDAQ:ENDP

Endo International plc, a specialty pharmaceutical company, manufactures and sells generic and branded pharmaceuticals in the United States and internationally. Its Branded Pharmaceuticals segment provides branded prescription products, including XIAFLEX to treat adult patients with Dupuytren's contracture; SUPPRELIN LA to treat central precocious puberty in children; NASCOBAL nasal spray to treat vitamin B12 deficiency; AVEED to treat hypogonadism; QWO, an injectable treatment for moderate to severe cellulite in the buttocks of adult women; PERCOCET to treat moderate-to-moderately-severe pain; TESTOPEL an implantable pellet indicated for TRT in conditions associated with a deficiency or absence of endogenous testosterone; EDEX to treat erectile dysfunction; LIDODERM a topical patch product containing lidocaine for the relief of pain; and products for the pain management and urology. The company's Sterile Injectables segment manufactures VASOSTRICT, a vasopressin injection; ADRENALIN, a non-selective adrenergic agonist; and APLISOL, which is a sterile aqueous solution, as well as generic sterile injectable products, including ertapenem for injections and ephedrine sulfate injections. Its Generic Pharmaceuticals segment offers solid oral extended-release, solid oral immediate-release, liquids, semi-solids, patches, powders, ophthalmic products, and sprays. The company's International Pharmaceuticals segment offers specialty pharmaceutical products in various therapeutic areas comprising attention deficit hyperactivity disorder, pain, women's health, oncology, and transplantation. The company sells its branded pharmaceuticals and generics to specialty physicians, retailers, clinics, government agencies, doctors, retail and specialty pharmacies, and specialty distributors. Endo International plc was founded in 1920 and is headquartered in Dublin, Ireland.

Eli Lilly and Company NYSE:LLY

$803.53 -15.85 (-1.93%)

Closing price 10/17/2025 03:59 PM Eastern

Extended Trading

$803.00 -0.53 (-0.07%)

As of 10/17/2025 07:59 PM Eastern

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Pfizer NYSE:PFE

$24.52 +0.29 (+1.18%)

Closing price 10/17/2025 03:59 PM Eastern

Extended Trading

$24.53 +0.02 (+0.06%)

As of 10/17/2025 07:59 PM Eastern

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Viking Therapeutics NASDAQ:VKTX

$33.53 -1.20 (-3.46%)

Closing price 10/17/2025 04:00 PM Eastern

Extended Trading

$33.63 +0.10 (+0.30%)

As of 10/17/2025 07:55 PM Eastern

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest VKTX, AMGN, LLY, ENDP, PFE, and ALT Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest VKTX, AMGN, LLY, ENDP, PFE, and ALT Earnings

Compare Dividends

Latest VKTX, AMGN, LLY, ENDP, PFE, and ALT Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

VKTX, AMGN, LLY, ENDP, PFE, and ALT Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

VKTX, AMGN, LLY, ENDP, PFE, and ALT Company Descriptions

Altimmune NASDAQ:ALT

Amgen NASDAQ:AMGN

Endo International NASDAQ:ENDP

Eli Lilly and Company NYSE:LLY

Pfizer NYSE:PFE

Viking Therapeutics NASDAQ:VKTX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools